Article Information
History
- March 9, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Yun Lu, PhD1,*,
- Arnstein Lindaas, MA2,†,
- Hector S Izurieta, MD, PhD1,
- Myrna Cozen, MPH2,
- Mikhail Menis, PharmD1,
- Xiangyu Shi, MS2,
- Whitney Steele, PhD1,
- Michael Wernecke, BA2,
- Yoganand Chillarige, MPA2,
- Jeffrey A Kelman, MD3 and
- Richard A Forshee, PhD1
- 1Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
- 2Acumen LLC, Burlingame, CA, USA
- 3Centers for Medicare & Medicaid Services, Washington, DC, USA
- ↵*CORRESPONDING AUTHOR CONTACT INFORMATION
Address correspondence to: Yun Lu, PhD. CBER/FDA, 10903 New Hampshire Avenue, Silver Spring, MD 20993; email: Yun.Lu{at}fda.hhs.gov; phone: 240-402-8704 - ↵†ALTERNATE CORRESPONDING AUTHOR CONTACT INFORMATION
Arnstein Lindaas, MA, Acumen LLC, 500 Airport Boulevard Suite 100, Burlingame, CA 94010; email: alindaas{at}acumenllc.com